Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

ced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Pittcon Organizing ... of Food Safety Tech , an e-Journal and producer ... an agreement for the second year for the co-location of ... 2014. The partnership provides that the registration fee to attend ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... On Thursday, December 9th, Mediaplanet published ... spearheading an industry-wide call to action advocating consumer ... us confront society,s most pressing challenges. By teaming ... Mediaplanet ,s ,Biotechnology, encourages appropriate policy action and ...
... China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: ... probiotics products in China, today announced that it has ... promissory notes for cash two days before the December ... notes were originally issued on December 11, 2007. The ...
... 8, 2010 Martek Biosciences Corporation (Nasdaq: MATK ... and fiscal year ended October 31, 2010. Total revenues for ... fourth quarter of fiscal 2009. Fourth quarter non-GAAP earnings per ... diluted share in last year,s fourth quarter.  For the full ...
Cached Biology Technology:The Biotechnology Industry Organization and Critical Path Institute Partner With Mediaplanet, Biocom, and the University of California Office to Spotlight the Science That Is Healing, Fueling and Feeding Our Global Population 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 3Martek Announces Fourth Quarter and FY 2010 Financial Results 2Martek Announces Fourth Quarter and FY 2010 Financial Results 3Martek Announces Fourth Quarter and FY 2010 Financial Results 4Martek Announces Fourth Quarter and FY 2010 Financial Results 5Martek Announces Fourth Quarter and FY 2010 Financial Results 6Martek Announces Fourth Quarter and FY 2010 Financial Results 7Martek Announces Fourth Quarter and FY 2010 Financial Results 8Martek Announces Fourth Quarter and FY 2010 Financial Results 9Martek Announces Fourth Quarter and FY 2010 Financial Results 10Martek Announces Fourth Quarter and FY 2010 Financial Results 11Martek Announces Fourth Quarter and FY 2010 Financial Results 12
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
(Date:4/23/2014)... manufacturers are turning away from using triclosan as an ... health concerns. And now scientists are reporting new evidence ... in the ACS journal Chemical Research in Toxicology ... substance called octylphenol, promoted the growth of human breast ... in mice. , Kyung-Chul Choi and colleagues note that ...
(Date:4/23/2014)... to date of the family of bacteria that ... strategies and reveals surprising findings about the bacteria,s ... public health strategies to control this respiratory disease, ... Genomic analysis of 343 strains of the ... collected over the last 100 years illustrates how ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
... photographic filter (S37100, Photographic Filters for ... ideal for black-and-white photography of gels ... gel stain, the safer ethidium bromide ... photographic filter is identical to the ...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
LAL Chromogenic Endpoint assay...
Biology Products: